Oncotelic Therapeutics, Inc. (OTLC) Stock Price & Analysis
Oncotelic Therapeutics, Inc. (OTLC) — price $0.02 (-4.76%), as of the Oct 5, 2026 trading session; market cap $8.87M.
Educational signal · not a buy or sell recommendation · How to read this
Oncotelic Therapeutics, Inc. · OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for orphan oncology indications.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.02 | |
| Change on the day | -4.76% | |
| 52-week range | $0.015 – $0.11 | |
| Market capitalisation | $8.87M | |
| Price / earnings (trailing) | 0.03 | |
| Shares traded on the day | 74.4K |
Price & events
Other perspectives
Council score for Oncotelic Therapeutics (OTLC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the OTLC film — every key number, told as a short cinematic story
~2 min · open the film
What is Oncotelic Therapeutics (OTLC), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Oncotelic Therapeutics, Inc. (OTLC) is the company analyzed here. It employs 41 people and is led by Vuong Trieu. In Q2 FY2026 it reported revenue of $250,000 and net income of $388,147. The market values it at $8.87M.
What do the latest results show for Oncotelic Therapeutics (OTLC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $250,000. Against analyst estimates the company has EPS beat 4 of 6 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $250,000 | $388,147 | $0.0008 (diluted) |
| Q1 FY2026 | $0 | -$2M | -$0.0049 (diluted) |
| Q4 FY2025 | $0 | $250M | $0.59 (diluted) |
| Q3 FY2025 | $0 | -$1M | -$0.0025 (diluted) |
What are the financial strengths and risks for Oncotelic Therapeutics (OTLC)?
Short answer
The distress and quality screens read Altman Z -0.06 · Piotroski F 5. Trailing ratios: ROE 0.0% · ROA 0.0% · current ratio 0.08 · free-cash-flow yield -11.5%.
The records behind this page
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Jul 10, 2026 (coverage not recorded)
- Transactions
- 13
- Identified insiders
- 6
- Purchases
- 7
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Investor Questions: OTLC Stock
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is OTLC a good stock to buy?
Stock Expert AI does not rate OTLC buy, sell or hold. Oncotelic Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the OTLC stock price today?
The last price recorded on this page for Oncotelic Therapeutics, Inc. (OTLC) is $0.02, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for OTLC?
Evaluate OTLC on fundamentals, analyst consensus, and risk factors. P/E: 0.03x. Focus on orphan oncology indications offers potential for accelerated regulatory pathways. Not financial advice.
How frequently does OTLC data refresh on this page?
OTLC's price is the last quote we recorded, from the Oct 5, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven OTLC's recent stock price performance?
Oncotelic Therapeutics, Inc. (OTLC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on orphan oncology indications. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OTLC overvalued or undervalued right now?
Oncotelic Therapeutics, Inc. (OTLC) trades at 0.03x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OTLC before investing?
Before investing in Oncotelic Therapeutics, Inc. (OTLC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OTLC to a portfolio?
Key strength of Oncotelic Therapeutics, Inc. (OTLC): Focus on orphan oncology indications. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (16 figures)
The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 10 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.02 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-06T06:44:38.894Z. | |
px.change | Change on the day | -4.76% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $8.87M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T20:00:00.000Z. Captured from FMP at 2026-10-06T06:44:36.804Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.001 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 0.03 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 74.4K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $250,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $388,147 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 13 transactions · 7 purchases, 0 sales, 6 other transactions · 6 identified insiders · available records within the last 180 days, newest dated Jul 10, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.015 – $0.11 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 · Expired observation | |
id.employees | Employees | 41 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 · Expired observation | |
id.ceo | Chief executive | Vuong Trieu | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 · Expired observation | |
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 6 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -0.06 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 0.0% · ROA 0.0% · current ratio 0.08 · free-cash-flow yield -11.5% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.